Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2024 | 07/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 12.40% | -68.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.40% | -74.07% | |||
| Operating Income | -12.40% | 74.07% | |||
| Income Before Tax | -9.51% | 84.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.51% | 84.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 100.00% | -50.00% | |||
| Net Income | -9.54% | 84.04% | |||
| EBIT | -12.40% | 74.07% | |||
| EBITDA | -13.64% | 75.65% | |||
| EPS Basic | -12.50% | 84.91% | |||
| Normalized Basic EPS | -20.00% | 72.22% | |||
| EPS Diluted | -12.50% | 84.91% | |||
| Normalized Diluted EPS | -20.00% | 72.22% | |||
| Average Basic Shares Outstanding | 0.00% | -0.22% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
